Dendritic cell immunotherapy in hepatitis C virus (HCV)-infected individuals.

Phase 1

Completed

• Conditions: Hepatitis C virus infection.; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Infection - Other infectious diseases

• Registration Number: ACTRN12611001134910
• Lead Sponsor: Eric J Gowans

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

HCV RNA positive for >6 months.
Previously failed interferon-based therapy.
Infected with genotype 1.

Exclusion Criteria

Evidence of liver infection with other hepatitis agents, viz. HAV, HBV.
HIV infection.
Evidence of autoimmunity.

Study & Design

• Study Type: Interventional
• Study Design: Not specified